Type I interferons for induction of remission in ulcerative colitis

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 9, 2015, Pages

  Wang, Yongjun ^a   Macdonald, John K ^a   Benchimol, Eric I ^b   Griffiths, Anne Marie ^c   Steinhart, A Hillary ^d   Panaccione, Remo ^e   Seow, Cynthia H ^f  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; PEGINTERFERON; PLACEBO; PREDNISOLONE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERFERON; ALPHA INTERFERON; ANTIINFLAMMATORY AGENT; BETA INTERFERON; ENEMA; INTERFERON;

APPLICATION SITE REACTION; ARTHRALGIA; BACKACHE; COLONOSCOPY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; HEADACHE; HISTOPATHOLOGY; HUMAN; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; RIGOR; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; COLITIS, ULCERATIVE; INDUCTION CHEMOTHERAPY; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; ENEMA; HUMANS; INDUCTION CHEMOTHERAPY; INTERFERON TYPE I; INTERFERON-ALPHA; INTERFERON-BETA; PREDNISOLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84964693816     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006790.pub3     Document Type: Review

References (86)

1. Madsen SM, Schlichting P, Davidsen B, Nielsen OH, Federspiel B, Riis P, et al. An open, randomized study comparing systemic interferon-a-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Gut 1999;45(Suppl V):A286.
2. Madsen SM, Schlichting P, Davidsen B, Nielsen OH, Federspiel B, Riis P, et al. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. American Journal of Gastroenterology 2001;96(6):1807-15.
3. Mannon P, Feagan B, Xi Y, McAllister A, Cataldi F. Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country-enrollment site in a phase IIa study with interferon-ß-1a. Journal of Crohn's and Colitis 2011;5(1):S102-3.
4. Mannon P, Miner P, Lukas M, McAllister A, Cataldi F. Secondary efficacy analysis from a phase IIa multicenter study with interferon-ß-1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology 2010;105:S468-9.
5. Mannon P, Panaccione R, Miner P, McAllister A, O'Gorman J, Cataldi F. Interferon-ß-1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology 2010;105:S446.
6. Mannon P, Reinisch W, Miner P, McAllister A, Xi Y, Cataldi F. Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post-hoc analysis in a phase 2a study with interferon-ß-1a. Journal of Crohn's and Colitis 2011;5(1):S69-70.
7. Mannon P, Reinisch W, Miner P, Xi Y, McAllister A, Cataldi F. Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon-ß-1a in ulcerative colitis. Journal of Crohn's and Colitis 2011;5(1):S94-5.
8. Mannon P, Reinisch W, Miner P, Xi Y, McAllister A, Cataldi F. Is there a difference between self-assessed patient-reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon-ß-1a. Journal of Crohn's and Colitis 2011;5(1):S84-5.
9. Miner P, Lembo A, Mannon P, Xi Y, McAllister A, Cataldi F. Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon-B-1a. Inflammatory Bowel Diseases 2011;17:S54-5.
10. Miner P, Mannon P, Rajagopalan K, McAllister A, Xi Y, Cataldi F. Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon-B-1a. Inflammatory Bowel Diseases 2011;17:S55.
11. Miner P, Mannon P, Zakko S, McAllister A, O'Gorman J, Cataldi F. Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon-B-1a in ulcerative colitis. Inflammatory Bowel Diseases 2011;17:S36.
12. Miner P, Zakko S, McAllister A, Cataldi F. Safety analysis from a phase IIa multicenter study with interferon-ß-1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology 2010;105:S433-4.
13. NCT00616434. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [: NCT00616434]
14. Reinisch W, Mannon P, Miner P, McAllister A, Xi Y, Cataldi F. Is elevated CRP a predictor of efficacy in ulcerative colitis? Post-hoc analysis from a placebo-controlled study with interferon-ß-1a. Journal of Crohn's and Colitis 2011;5(1):S72-3.
15. Musch E, Andus T, Kruis W, Raedler A, Spehlmann M, Schreiber S, et al. Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clinical Gastroenterology and Hepatology 2005;3(6):581-6.
16. Musch E, Raedler A, Andus T, Kruis W, Schreiber S, Lorenz A, et al. A phase II. placebo-controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta-1a in patients with ulcerative colitis. Gastroenterology 2002;122(4 Suppl 1):A431.
17. Musch E, Raedler A, Andus T, Kruis W, Schreiber S, Lorenz A, et al. Results of a randomised, double-blind, placebo-controlled, multi-centre, phase-II. study to test the effectivity and tolerance of Interferon-beta-1a (CHO-beta) [rIFN-beta-1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie 2002;40(8):705.
18. Nikolaus S, Rutgeerts P, Fedorak R, Steinhart AH, Wild GE, Theuer D, et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 2003;52(9):1286-90.
19. Nikolaus S, Rutgeerts P, Fedorak RN, Steinhart H, Wild GE, Theuer D, et al. Recombinant human interferon-beta (IFNb-1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology 2001;120(5 Suppl 1):A454.
20. Pena-Rossi C, Schreiber S, Golubovic G, Mertz-Nielsen A, Panes J, Rachmilewitz D, et al. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II. study of subcutaneous interferon-beta-la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics 2008;28(6):758-67.
21. Tilg H, Vogelsang H, Ludwiczek O, Lochs H, Colombel JF, Rutgeerts P, et al. A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology 2003;124(4 Suppl 1):A62.
22. Tilg H, Vogelsang H, Ludwiczek O, Lochs H, Kaser A, Colombel JF, et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003;52(12):1728-33.
23. Bargiggia S, Thorburn D, Anderloni A, Ardizzone S, Giorgi A, Porro GB, et al. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Alimentary Pharmacology and Therapeutics 2005;22(3):209-15.
24. Hadziselimovic F, Schaub U, Emmons LR. Interferon alpha-2A (roferon) as a treatment of inflammatory bowel disease in children and adolescents. Advances in Experimental Medicine and Biology 1995;371B:1323-6.
25. Maev IV, Grigorian SS, Gadzhieva MG, Ovchinnikova NI, Ospel'nikova TP, Kaziulin AN. [Interferon status of patients with non-specific ulcerous colitis and its correction with interferon inducers]. Terapevticheskiv Arkhiv 2002;74(2):31-5.
26. Cataldi F, Mannon P, Fuss I, Groden C, Strober W. A phase IIa study of AVONEX (interferon-B-1a) in ulcerative colitis (UC): Integrating basic immunology and human pilot study results. Journal of Crohn's and Colitis Supplements 2010;4(1):33.
27. Mannon PJ, Hornung RL, Yang Z, Yi C, Groden C, Friend J, et al. Suppression of inflammation in ulcerative colitis by interferon-ß-1a is accompanied by inhibition of IL-13 production. Gut 2011;60(4):449-55.
28. Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis - an open long-term pilot trial. Alimentary Pharmacology and Therapeutics 2002;16(7):1233-9.
29. Musch E, Andus T, Malek M, Chrissafidou A, Schulz M. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial. Zeitschrift für Gastroenterologie 2007;45(12):1235-40.
30. Sümer N, Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. European Journal of Gastroenterology and Hepatology 1995;7(7):597-602.
31. Anonymous. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352(9139):1498-504.
32. Anonymous. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56(12):1628-36.
33. Antonetti F, Finocchiaro O, Mascia M, Terlizzese MG, Jaber A. A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis. Journal of Interferon & Cytokine Research 2002;22(12):1181-4.
34. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369(9573):1627-40.
35. Beattie RM, Nicholls SW, Domizio P, Williams CB, Walker-Smith JA. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. Journal of Pediatric Gastroenterology and Nutrition 1996;22(4):373-9.
36. Bernstein CN. Treatment of IBD: where we are and where we are going. American Journal of Gastroenterology 2015;110(1):114-26.
37. Borg FA, Isenberg DA. Syndromes and complications of interferon therapy. Current Opinion in Rheumatology 2007;19(1):61-6.
38. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nature reviews. Immunology 2003;3(7):521-33.
39. Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. Journal of Leukocyte Biology 2002;71(4):565-81.
40. Durbin RK, Kotenko SV, Durbin JE. Interferon induction and function at the mucosal surface. Immunological Reviews 2013;255(1):25-39.
41. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
42. Ek WE, D'Amato M, Halfvarson J. The history of genetics in inflammatory bowel disease. Annals of Gastroenterology 2014;27(4):294-303.
43. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2013;369(8):699-710.
44. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 1992;45(7):769-73.
45. Foster GR. Review article: pegylated interferons: chemical and clinical differences. Alimentary Pharmacology and Therapeutics 2004;20(8):825-30.
46. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacology & Therapeutics 2012;135(1):44-53.
47. Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmunity Reviews 2014;13(1):3-10.
48. Ghosh S, Chaudhary R, Carpani M, Playford R. Interfering with interferons in inflammatory bowel disease. Gut 2006;55(8):1071-73.
49. Graber JJ, Ford D, Zhan M, Francis G, Panitch H, Dhib-Jalbut S. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. Journal of Neuroimmunology 2007;185(1-2):168-74.
50. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96(3):804-10.
51. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
52. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflammatory Bowel Diseases 2006;12 Suppl 1:S3-9.
53. Hansen R, Thomson JM, El-Omar EM, Hold GL. The role of infection in the aetiology of inflammatory bowel disease. Journal of Gastroenterology 2010;45(3):266-76.
54. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129(2):550-64.
55. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
56. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
57. Hoofnagle JH, SeeffLB. Peginterferon and ribavirin for chronic hepatitis C. New England Journal of Medicine 2006;355(23):2444-51.
58. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nature reviews. Immunology 2014;14(1):36-49.
59. Jovanovic K, Siebeck M, Gropp R. The route to pathologies in chronic inflammatory diseases characterized by T helper type 2 immune cells. Clinical and Experimental Immunology 2014;178(2):201-11.
60. Kasper LH, Reder AT. Immunomodulatory activity of interferon-beta. Annals of Clinical and Translational Neurology 2014;1(8):622-31.
61. Ko Y, Butcher R, Leong RW. Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseases. World Journal of Gastroenterology 2014;20(5):1238-47.
62. Koretz RL, Pleguezuelo M, Arvaniti V, Barrera Baena P, Ciria R, Gurusamy KS, et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD003617.pub2]
63. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990;336(8706):16-9.
64. Ludigs K, Parfenov V, Du Pasquier RA, Guarda G. Type I IFN-mediated regulation of IL-1 production in inflammatory disorders. Cellular and Molecular Life Sciences 2012;69(20):3395-418.
65. Mavrogiannis C, Papanikolaou IS, Elefsiniotis IS, Psilopoulos DI, Karameris A, Karvountzis G. Ulcerative colitis associated with interferon treatment for chronic hepatitis C. Journal of Hepatology 2001;34(6):964-5.
66. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. Journal of Hepatology 1996;25(3):283-91.
67. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scandinavian Journal of Gastroenterology 1978;13(7):833-7.
68. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298(6666):82-6.
69. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2005;353(23):2462-76.
70. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine 1987;317(26):1625-9.
71. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
72. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. American Journal of Gastroenterology 1992;87(8):971-6.
73. Shibuya H, Hirohata S. Differential effects of IFN-alpha on the expression of various TH2 cytokines in human CD4+ T cells. Journal of Allergy and Clinical Immunology 2005;116(1):205-12.
74. Sparano JA, Dutcher JP, Kaleya R, Caliendo G, Fiorito J, Mitsudo S, et al. Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. Cancer 1991;68(7):1538-44.
75. Sprenger R, Sagmeister M, Offner F. Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis. Gut 2005;54(3):438-9.
76. Tada H, Saitoh S, Nakagawa Y, Hirana H, Morimoto M, Shima T, et al. Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C. Journal of Gastroenterology 1996;31(4):582-4.
77. Timmer A, McDonald JWD, Tsoulis DJ, MacDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD000478.pub3]
78. Travis SP. Review article: induction therapy for patients with active ulcerative colitis. Alimentary Pharmacology and Therapeutics 2006;24 Suppl 1:10-6.
79. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61(4):535-42.
80. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. British Medical Journal 1955;2(4947):1041-8.
81. Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. American Journal of Gastroenterology 2002;97(11):2820-8.
82. Tursi A. Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C. Inflammatory Bowel Diseases 2007;13(9):1189-90.
83. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998;43(1):29-32.
84. Watanabe T, Inoue M, Harada K, Homma N, Uchida M, Ogata N, et al. A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin. Gut 2006;55(11):1682-3.
85. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World Journal of Gastroenterology 2014;20(1):91-9.
86. Seow CH, Benchimol EI, Griffiths AM, Steinhart AH. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006790.pub2]